Table 2 Cochrane risk of bias for randomized controlled trials
Author (Year) | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data addressed | Selective reporting | Other sources of biasa |
|---|---|---|---|---|---|---|---|
Ahmed (2016) [50] |
|
|
|
|
|
|
|
Akbarzadeh (2017) [47] |
|
|
|
|
|
|
|
Bigelow (2014) [35] |
|
|
|
|
|
|
|
Boulvain (2004) [60] |
|
|
|
|
|
|
|
Buultjens (2018) [41] |
|
|
|
|
|
|
|
Çiftçi and Arikan (2011) [38] |
|
|
|
|
|
|
|
Escobar (2001) [61] |
|
|
|
|
|
|
|
Franco-Antonio (2022) [39] |
|
|
|
|
|
|
|
Galland (2017) [64] |
|
|
|
|
|
|
|
Gureje (2019) [42] |
|
|
|
|
|
|
|
Hans (2018) [52] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Kenyon (2016) [45] |
|
|
|
|
|
|
|
Langer (1998) [48] |
|
|
|
|
|
|
|
Lieu (2000) [62] |
|
|
|
|
|
|
|
Liu (2018) [36] |
|
|
|
|
|
|
|
Lutenbacher (2018) [46] |
|
|
|
|
|
|
|
Mohd Shukri (2019) [55] |
|
|
|
|
|
|
|
Montazeri (2020) [57] |
|
|
|
|
|
|
|
Morrell (2000) [56] |
|
|
|
|
|
|
|
Nikodem (1993) [63] |
|
|
|
|
|
|
|
Rossouw (2021) [53] |
|
|
|
|
|
|
|
Rotheram-Fuller (2017) [58] |
|
|
|
|
|
|
|
Saatsaz (2016) [49] |
|
|
|
|
|
|
|
Sainz Bueno (2005) [51] |
|
|
|
|
|
|
|
Song (2017) [37] |
|
|
|
|
|
|
|
Tubay (2019) [59] |
|
|
|
|
|
|
|
Vidas (2011) [40] |
|
|
|
|
|
|
|
Zhao (2017) [54] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- aOther sources of bias may include protocol adherence, other interventions avoided, sample size sufficiently large, eligible participants enrolled, funding and sponsorship bias
-
, yes;
, no;
, unclear
, yes;
, no;
, unclear